Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Characterization and optimization of the novel TRPM2 antagonist tatM2NX.

Cruz-Torres I, Backos DS, Herson PS.

Mol Pharmacol. 2019 Nov 26. pii: mol.119.117549. doi: 10.1124/mol.119.117549. [Epub ahead of print]

2.

Reversal of Global Ischemia-Induced Cognitive Dysfunction by Delayed Inhibition of TRPM2 Ion Channels.

Dietz RM, Cruz-Torres I, Orfila JE, Patsos OP, Shimizu K, Chalmers N, Deng G, Tiemeier E, Quillinan N, Herson PS.

Transl Stroke Res. 2019 Jun 28. doi: 10.1007/s12975-019-00712-z. [Epub ahead of print]

PMID:
31250378
3.

Experimental pediatric stroke shows age-specific recovery of cognition and role of hippocampal Nogo-A receptor signaling.

Orfila JE, Dietz RM, Rodgers KM, Dingman A, Patsos OP, Cruz-Torres I, Grewal H, Strnad F, Schroeder C, Herson PS.

J Cereb Blood Flow Metab. 2019 Feb 14:271678X19828581. doi: 10.1177/0271678X19828581. [Epub ahead of print]

PMID:
30762478
4.

Long-term depression in Purkinje neurons is persistently impaired following cardiac arrest and cardiopulmonary resuscitation in mice.

Quillinan N, Deng G, Shimizu K, Cruz-Torres I, Schroeder C, Traystman RJ, Herson PS.

J Cereb Blood Flow Metab. 2017 Aug;37(8):3053-3064. doi: 10.1177/0271678X16683691. Epub 2016 Dec 19.

5.

Extended therapeutic window of a novel peptide inhibitor of TRPM2 channels following focal cerebral ischemia.

Shimizu T, Dietz RM, Cruz-Torres I, Strnad F, Garske AK, Moreno M, Venna VR, Quillinan N, Herson PS.

Exp Neurol. 2016 Sep;283(Pt A):151-6. doi: 10.1016/j.expneurol.2016.06.015. Epub 2016 Jun 15.

Supplemental Content

Loading ...
Support Center